New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations of cost, inconvenience, toxic effects, efficacy of retreatment and lack of survival benefit should focus future clinical research on more-effective induction strategies.
Related Articles
Impact Factor
Follicular lymphoma: side-lined drug excites new interest
Senza categoria
Newsround
Impact Factor
Leave a Reply